IFNA1 and hypertensive disorder: In addition, Kiladjian (2018) reported that, after cross-over from IFN to RUX, no patient out of 13 recruited was reported to have HTN in the RESPONSE trial, whereas only 1 out of 8 patients recruited developed HTN as a grade 1/2 adverse event in the RESPONSE-2 trial (13.5/100 patient-years of exposure) [83].